Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Eisai

Tracked across 25 events · 265 articles · First seen Apr 21, 2022 · Last active Sep 22, 2026

Sentiment
15
Attention
6
Events
25
Relationships
12
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Business
Impact: Eisai is the primary actor, launching Leqembi in India, which could drive revenue growth and strengthen its position in the Alzheimer's treatment market.
Aug 03, 2026 · 6 articles
4 85
Business
Impact: Partner responsible for development and commercialization; launched Leqembi Iqlik in the US, expanding its Alzheimer's franchise.
Aug 24, 2026 · 6 articles
4 80
Regulatory
Impact: Eisai is the global commercialization partner for Leqembi. The recommendation supports broader market access in Canada, potentially increasing sales and revenue.
Sep 01, 2026 · 6 articles
4 70
Business
Impact: Eisai, as the primary developer and commercializer of Lecanemab, presented the sales simulation, indicating strong future revenue growth for the company. This positively impacts its financial projections and market position.
May 25, 2026 · 7 articles
6 -80
Tech
Impact: Eisai co-produces lecanemab (Leqembi), an anti-amyloid drug whose effectiveness was disputed by the Cochrane review, potentially leading to financial repercussions.
Apr 16, 2026 · 6 articles
2 40
Regulatory
Impact: Manufacturer of lecanemab; requested reconsideration leading to favorable recommendation, potentially increasing drug sales.
Jul 16, 2026 · 7 articles
2 50
Business
Impact: Eisai reported Leqembi sales of JPY 29.3 billion in Q2 2026, driving its revenue and partnership with Biogen.
Jul 29, 2026 · 6 articles
2 20
Tech
BioArctic announced that Leqembi (lecanemab), the first therapy targeting an underlying cause of Alzheimer's disease, is now available at a private clinic in Sweden and that the first patient has started treatment. This marks the…
Impact: Eisai leads global clinical development and commercialization of Leqembi and worked with BioArctic to enable Swedish patient access. The Swedish launch adds incremental commercial reach in the Nordics.
Sep 22, 2026 · 7 articles
2 -20
Business
Impact: Eisai's Eribulin Injection is the reference listed drug for the newly approved generic Eribulin Mesylate Injection, indicating potential competition and market share impact for Eisai.
Jun 03, 2026 · 8 articles
4 -30
International
Impact: Eisai's stock tumbled and declined, contributing to the negative performance of some pharmaceutical companies.
May 18, 2026 · 23 articles
3 45
Tech
Impact: Key member; contributes to the consortium's research efforts.
Jul 13, 2026 · 6 articles
6 40
International
Impact: Eisai is expected to announce investments and collaborations in life sciences as part of the broader UK-Japan agreements.
Jun 13, 2026 · 26 articles
4 20
Business
Impact: Eisai gained more than 3% on one day, reflecting gains.
Jul 24, 2026 · 37 articles
4 -30
Business
The Japanese stock market experienced a significant rally over several trading sessions in August 2026, with the Nikkei 225 index surging to record levels above 68,000. The rally was driven by strong gains in technology…
Impact: Eisai declined almost 4%, underperforming the market.
Apr 21, 2022 · 26 articles
2 10
Tech
Impact: Greta Duréel has consulted for Eisai, but no direct impact from this study.
Aug 12, 2026 · 14 articles
2 0
Business
Impact: Eisai is BioArctic's partner for Leqembi, responsible for regulatory interactions and commercialization globally, indicating a significant collaboration for BioArctic's key product.
May 28, 2026 · 9 articles
1 0
Business
Impact: Eisai is mentioned as BioArctic's partner in developing and commercializing Leqembi.
May 29, 2026 · 6 articles
4 0
Business
Impact: Eisai, in collaboration with Biogen, developed Leqembi, one of the FDA-approved monoclonal antibody treatments for Alzheimer's Disease, which requires a positive beta-amyloid brain scan.
Jul 06, 2026 · 6 articles
0 0
Business
Impact: Eisai is BioArctic's partner for Leqembi commercialization. The Q2 report may include updates on Leqembi sales, but no specific impact is announced.
Aug 19, 2026 · 6 articles
2 0
Business
Impact: Eisai is BioArctic's partner for Leqembi, but is not directly involved in this collaboration. The event does not materially affect Eisai.
Aug 19, 2026 · 6 articles
0 0
Business
Impact: Eisai is BioArctic's partner for Leqembi, but this share issuance does not affect Eisai directly. The event is unrelated to their collaboration.
Aug 31, 2026 · 8 articles
4 0
Business
May 15, 2026 · 6 articles
2 0
Business
May 13, 2026 · 7 articles
4 0
Regulatory
May 08, 2026 · 14 articles
2 0
Business
Apr 21, 2026 · 6 articles
BioArctic licensee ↔ Eisai Eisai is a global pharmaceutical company that licenses proprietary technologies
BioArctic licensor ↔ Eisai BioArctic is a research-based biopharma company that licenses its proprietary te
Biogen ↔ Eisai
Biogen ↔ Eisai
Japan ↔ Eisai
Japan ↔ Eisai
China ↔ Eisai
China ↔ Eisai
ERGEN INTELLIGENCE
Track Eisai live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.